A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast

A Chiricozzi, D Caposiena, V Garofalo… - Expert review of …, 2016 - Taylor & Francis
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …
被引用次数：62 相关文章

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.

A Chiricozzi, D Caposiena, V Garofalo… - Expert Review of …, 2016 - europepmc.org
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …

A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast

A Chiricozzi, D Caposiena, V Garofalo… - EXPERT REVIEW OF …, 2015 - arpi.unipi.it
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast

A Chiricozzi, D Caposiena, V Garofalo… - EXPERT REVIEW OF …, 2016 - publicatt.unicatt.it
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast

A Chiricozzi, D Caposiena… - Expert review of …, 2016 - pubmed.ncbi.nlm.nih.gov
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …